赛诺菲和再生元公司报告了针对IL-33通路的COPD药物的混合三期试验结果Sanofi and Regeneron Report Mixed Phase 3 Results for COPD Drug Targeting IL-33 Pathway

动脉网 · May 30 19:09

by Mark Chiang

马克·蒋

Share To

分享到

Sanofi and Regeneron have released findings from two Phase 3 clinical trials evaluating their experimental drug, itepekimab, for chronic obstructive pulmonary disease (COPD). The results showed a mixed outcome, with the drug demonstrating some positive effects but failing to meet certain key benchmarks.

赛诺菲和再生元公司发布了两项评估其试验性药物伊替匹单抗（itepekimab）用于慢性阻塞性肺疾病（COPD）的III期临床试验结果。结果显示，该药物的结果好坏参半，虽然表现出一些积极效果，但未能达到某些关键指标。

Following the announcement, both companies experienced a decline in their stock prices..

公告发布后，两家公司的股价均出现下跌。

The studies assessed itepekimab’s efficacy in reducing exacerbations among COPD patients who were former smokers. While the drug showed potential in lowering flare-ups compared to standard treatments, it did not achieve statistically significant improvements across all primary endpoints. The trials aimed to explore whether targeting interleukin-33 (IL-33), an inflammatory pathway linked to COPD progression, could offer new therapeutic benefits.

这些研究评估了伊替普单抗在减少曾吸烟的慢性阻塞性肺病（COPD）患者急性加重方面的疗效。尽管该药物在降低病情恶化方面相比标准治疗显示出潜力，但在所有主要终点上未达到统计学显著改善。试验旨在探索针对白细胞介素-33（IL-33）这一与COPD进展相关的炎症通路，是否能提供新的治疗益处。

Sanofi and Regeneron are continuing to analyze the data as they evaluate next steps for the development of itepekimab..

赛诺菲和再生元将继续分析数据，以评估下一步如何开发伊替匹单抗。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI驱动

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: May 30, 2025

日期：2025年5月30日

DrugPatentWatch Article Details Methods for Identifying Factors Influencing Drug Pricing and Revenue Growth

DrugPatentWatch 文章详细介绍了识别影响药品定价和收入增长因素的方法

Drug Patent Watch: Strategies to Manage Costs of Litigation by Thorough Patent Landscaping.

药品专利观察：通过全面的专利布局管理诉讼成本的策略。

FDA Approves Bristol Myers Squibb’s Opdivo and Yervoy Combination Immunotherapy

FDA批准百时美施贵宝的Opdivo和Yervoy联合免疫疗法

Drug Patent Watch Strategy Includes Patent Mapping to Inform Business Decisions

药物专利观察战略包括专利图谱以指导商业决策

[email protected]

电子邮件地址

Author

作者

Mark Chiang

蒋志光